Summit Therapeutics Inc. (SMMT)

USD 16.98

(-8.56%)

Market Cap (In USD)

12.51 Billion

Revenue (In USD)

-

Net Income (In USD)

-614.92 Million

Avg. Volume

4.75 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.1-33.89
PE
-
EPS
-
Beta Value
-0.923
ISIN
US86627T1088
CUSIP
86627T108
CIK
1599298
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robert W. Duggan
Employee Count
-
Website
https://www.summittxinc.com
Ipo Date
2015-03-05
Details
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.